BOULDER, Colo. (November 10, 2023) — SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced findings from key studies demonstrating the broad and deep role proteomics plays in detecting cardiovascular risk, achieving optimal cardiometabolic health, and assessing

Revenue of $22.0 million, reflecting 14% year-over-year growth when excluding royalty revenue from NEB in the corresponding prior-year period Cash and investments of over $450 million Raising full year 2023 revenue guidance to $82 million to $85 million Management to host conference call today at

Expanded menu gives researchers broadest coverage of the proteome for increased discovery of biomarkers and drug targets BOULDER, Colo., Nov. 01, 2023 (GLOBE NEWSWIRE) -- SomaLogic Inc., (Nasdaq:SLGC), a leader in data-driven proteomics technology, today announced the launch of its high-plex

BOULDER, Colo., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the third quarter 2023 after market close on November 8, 2023. Management will host a corresponding conference call beginning at 4:30 p.m.

ctivates Standard BioTools’ strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights Expands commercial reach with substantial

DNA Link will bring the power of the largest proteomics platform available to their biomarker discovery and drug development work BOULDER, Colo. and SEOUL, Korea, Sept. 19, 2023 (GLOBE NEWSWIRE) -- SomaLogic Inc., (Nasdaq:SLGC), a leader in data-driven proteomics technology, today announced its

SomaLogic’s SomaScan® platform was used to target 15 markers shared among all cancer types. BOULDER, Colo., Sept. 12, 2023 (GLOBE NEWSWIRE) -- In a new paper published in Nature's Scientific Reports , researchers at SomaLogic Inc. studied the value of protein biomarkers in the early detection of

Novo Nordisk will extend its use of SomaLogic’s innovative proteomics technologies for research in cardiometabolic and other diseases BOULDER, Colo., Sept. 05, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today that it is extending its collaborative

Revenue of $20.5 million, an increase of 45% year-over-year Cash and investments of approximately $474 million, a strong capital position to fund current and future business initiatives Reiterating full year 2023 revenue guidance and operating expense target Management to host conference call today

BOULDER, Colo., July 24, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the second quarter 2023 after market close on August 14 th , 2023. Management will host a corresponding conference call beginning at 4:30